PMID: 11345205May 10, 2001Paper

Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group

International Journal of Hematology
A MatsuzakiJ Okamura

Abstract

We analyzed the long-term outcome and late effects of treatment in 187 patients with childhood acute lymphoblastic leukemia (ALL) diagnosed between 1984 and 1990. Overall survival and event-free survival rates were 68.2% +/- 3.7% and 63.2% +/- 3.6% at 15 years, respectively. Of 55 patients who relapsed after achieving the first complete remission (CR), only 17.4% were rescued by salvage therapy. The advantage of stem cell transplantation over chemotherapy was observed only in those patients with bone marrow relapse during therapy. The SD for score height in patients maintaining the first CR significantly decreased at the time of final follow-up compared with that at diagnosis: 0.059 to -0.800 (P < .0001). The decrease was remarkable in patients younger than 5 years at diagnosis. Other late effects included mild liver dysfunction in 18% and hepatitis C virus infection in 9%. Congestive heart failure was observed in only 2.9% of patients despite the high cumulative dose of daunorubicin (450 mg/m2). Although the survival rates of patients on our protocols were comparable to those of other study groups, some modification, including reduction in dose of cranial irradiation and/or anticancer drugs, should be considered to reduce late...Continue Reading

References

Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R TrueworthyM Haggard
Dec 1, 1991·Archives of Disease in Childhood·M UruenaA D Leiper
Nov 7, 1991·The New England Journal of Medicine·J P NegliaG D Hammond
Sep 1, 1987·British Journal of Cancer·M M HawkinsJ E Kingston
Feb 27, 1988·Lancet·P E ClaytonD A Price
Jul 1, 1995·Pediatric Research·J E Van Dongen-MelmanR M Egeler
Aug 1, 1994·Archives of Disease in Childhood·I OdameM D Donaldson
Jan 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D Pinkel
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B BeyermannG Henze
Feb 19, 1998·The New England Journal of Medicine·W E EvansC H Pui
Dec 16, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A W WalterL E Kun

❮ Previous
Next ❯

Citations

Jul 8, 2011·The Cochrane Database of Systematic Reviews·Renée L MulderLeontien Cm Kremer
Sep 5, 2014·The Cochrane Database of Systematic Reviews·Elvira C van DalenLeontien C M Kremer
Apr 28, 2006·Pediatric Blood & Cancer·Patrick ManskyCrystal Mackall
Apr 16, 2019·The Cochrane Database of Systematic Reviews·Renée L MulderElvira C van Dalen
May 6, 2019·Journal of Cancer Survivorship : Research and Practice·Long Hin Jonathan PoonYin Ting Cheung
Jul 20, 2016·World Journal of Gastroenterology : WJG·Elio CastagnolaAlfredo Guarino
Apr 7, 2021·Japanese Journal of Clinical Oncology·Hideki NakayamaJun Okamura

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.